Syndax Pharmaceuticals (SNDX) Earnings: Q3 2026 Results

The quarter ended September 30, 2026 and Syndax Pharmaceuticals published the results on November 2, 2026. Revenue and diluted EPS are shown against Q3 2025, the same quarter a year earlier, which takes seasonal swings out of the comparison.

• Niktimvo sales are recorded by Incyte. Syndax Pharmaceuticals books 50% of Niktimvo net commercial profit as collaboration revenue, so the $22.6 million on this page comes from $67.4 million of Niktimvo net revenue.
• Q3 2026 cost of product sales includes a one-time $10.0 million sales-based milestone payment to AbbVie tied to Revuforj.

Source: Syndax Pharmaceuticals Q3 2026 results, November 2, 2026. Also in the Form 10-Q for the quarter ended September 30, 2026. Figures as reported; checked against the release on November 10, 2026.

How Syndax Pharmaceuticals splits revenue in its own release, under its own labels, for Q3 2026 against Q3 2025. Indented lines are parts of the line above them.

• Syndax Pharmaceuticals's Revuforj product revenue, net revenue was $60.7 million in Q3 2026, up 90% from $32.0 million in Q3 2025, 73% of total revenue.
• Syndax Pharmaceuticals's Niktimvo collaboration revenue, net revenue was $22.6 million in Q3 2026, up 63% from $13.9 million in Q3 2025, 27% of total revenue.

Segment lines are the figures writers cite most often, because they show where the growth in a quarter came from. Companies redraw their segments from time to time and restate the prior year to match, so a year-ago figure here can differ from the one printed a year ago. When that has happened, the note above says so.

From the earnings release

Syndax Pharmaceuticals gives no revenue or EPS guidance in its release; its only numeric outlook is for operating expenses.

In its Q3 2026 release, Syndax Pharmaceuticals said:

“For the full year of 2026, the Company continues to expect total research and development plus selling, general and administrative expenses to be approximately $400 million, excluding the impact of $50 million in estimated non-cash stock compensation expense.”

Source: Syndax Pharmaceuticals Q3 2026 release, Nov 2, 2026.

This is the company's own guidance as of Nov 2, 2026, quoted as given. Walnut does not make forecasts of its own. Analyst estimates for the coming quarters are on the SNDX forecast page.

Revenue and diluted EPS for the last 5 quarters. Each date links to that quarter's release.

GAAP total revenues and basic and diluted loss per share, each as first reported in that quarter's release.

We do not hold a confirmed date for Syndax Pharmaceuticals's next report. Companies post the date on their investor relations site a few weeks ahead, usually with the time of the conference call.

Each quarter keeps its own page with the figures as reported, so a link to one stays pointed at the same numbers after the next report.

• Q3 2026 (this page), reported Nov 2, 2026

Syndax Pharmaceuticals reported Q3 2026 total revenue of $83.3 million, up 82% from $45.9 million. Two medicines make up all of it: $60.7 million of net revenue from Revuforj (revumenib), its menin inhibitor for relapsed or refractory acute leukemia, and $22.6 million of collaboration revenue from Niktimvo (axatilimab-csfr), its chronic graft-versus-host disease antibody. (Syndax Pharmaceuticals Q3 2026 release, Nov 2, 2026)

Revuforj net revenue rose 90% from a year earlier and 11% from Q2 2026. Syndax said new patients rose about 20% and total prescriptions about 13% from the prior quarter, helped by patients with KMT2A-rearranged or NPM1-mutated leukemia resuming Revuforj after a stem cell transplant. It cites claims data showing approximately 50% of relapsed KMT2Ar patients proceed to transplant after Revuforj, and about 60% of those resume therapy. (Syndax Pharmaceuticals Q3 2026 release, Nov 2, 2026)

Niktimvo is co-commercialized with Incyte, which records the sales. Niktimvo net revenue was $67.4 million, up 47%, and Syndax records 50% of the net commercial profit (net revenue minus cost of sales and commercial expenses) as collaboration revenue. The 10-Q attributes the rise to higher sales volume from increased brand awareness. (Syndax Pharmaceuticals Q3 2026 release, Nov 2, 2026; Syndax Pharmaceuticals Form 10-Q, Q3 2026, Nov 2, 2026)

Part of Niktimvo's U.S. sales is committed elsewhere: under a November 2024 agreement Royalty Pharma paid $350.0 million upfront for a 13.8% royalty on quarterly U.S. Niktimvo net sales. Syndax records that as a royalty interest financing liability, which produced $11.8 million of royalty interest expense in Q3 2026. (Syndax Pharmaceuticals Form 10-Q, Q3 2026, Nov 2, 2026)

Syndax Pharmaceuticals reported a net loss attributable to common stockholders of $49.4 million in Q3 2026, $0.55 per share, against $60.7 million, or $0.70, a year earlier. It reports only GAAP loss per share, on 89,789,842 weighted average shares. (Syndax Pharmaceuticals Q3 2026 release, Nov 2, 2026)

Research and development expenses rose to $67.5 million from $56.3 million, mainly for frontline trials of revumenib combined with standard-of-care agents in AML; revumenib-related R&D alone was $34.7 million. Selling, general and administrative expenses fell to $43.7 million from $44.9 million because 2025 carried launch costs for both products. (Syndax Pharmaceuticals Q3 2026 release, Nov 2, 2026; Syndax Pharmaceuticals Form 10-Q, Q3 2026, Nov 2, 2026)

Cost of product sales rose to $14.0 million from $2.1 million, mainly because of a one-time $10.0 million sales-based milestone payment to AbbVie plus royalties on higher Revuforj sales. Other charges below operating loss were royalty interest expense of $11.8 million and $1.2 million of interest on the $250.0 million of 2.25% Convertible Senior Notes due 2031 issued in June 2026, against interest income of $5.6 million. (Syndax Pharmaceuticals Form 10-Q, Q3 2026, Nov 2, 2026; Syndax Pharmaceuticals Q3 2026 release, Nov 2, 2026)

Diluted EPS divides net income by the weighted average number of shares outstanding in the quarter, plus the shares that options and other equity awards could add. Buybacks shrink that count and lift EPS for the same profit; share issuance and stock awards enlarge it.

Syndax Pharmaceuticals does not give revenue guidance. Its only numeric outlook is for expenses: for full year 2026 it continues to expect research and development plus selling, general and administrative expenses of approximately $400 million, excluding about $50 million of non-cash stock compensation. It says its cash and investments, together with product revenue, collaboration revenue and interest income, will enable it to reach profitability. (Syndax Pharmaceuticals Q3 2026 release, Nov 2, 2026)

Upcoming events Syndax names include new revumenib frontline combination data in Q4 2026, topline data from the Phase 2 axatilimab and ruxolitinib trial in Q1 2027, and the Phase 3 axatilimab and corticosteroid trial readout in early 2028. In October 2026 the MAXPIRe Phase 2 trial of axatilimab in idiopathic pulmonary fibrosis missed its primary endpoint, and Syndax ended development there. (Syndax Pharmaceuticals Q3 2026 release, Nov 2, 2026)

A consensus figure is the average of the models published by the analysts who cover Syndax Pharmaceuticals, collected by a data provider and revised up to the day of the report. A quarter that lands above it says how expectations were set as much as how the business did, and the share price on the day also reflects the guidance and the lines no consensus covers.

The consensus figures on this page are Yahoo Finance's, as pulled on the date shown. Each comes with the number of analysts behind it; the smaller that number, the more one revised estimate can move the average.

The figures below are the ones Syndax Pharmaceuticals's own release and filings put weight on for Q3 2026, with the latest reported value for each.

What the quarter means for a holding is a separate question from what it reported. The case for and against owning SNDX is on is SNDX a buy or a sell?, what analysts expect next is on the SNDX forecast, and what the company does is on the Syndax Pharmaceuticals (SNDX) stock page.

Every number on this page can be traced to a document Syndax Pharmaceuticals published. Checking one takes a couple of minutes, and it is worth doing before you quote a figure anywhere.

• The results release is the document linked in the source line above. Companies publish it on their investor relations site at the moment results go out, and it carries the headline tables: revenue, operating income, net income and EPS for the quarter and the year-ago quarter.
• The same release is filed with the SEC as Exhibit 99.1 to a Form 8-K under Item 2.02, usually on the day of the report. The SEC copy does not change after the fact, which makes it the safer thing to link when you cite a number.
• The quarterly report (Form 10-Q) follows within a few weeks and carries the full financial statements, the segment note and management's discussion of what changed. The fourth quarter is covered by the annual report (Form 10-K) instead.
• Restated comparisons are flagged in the notes on this page. When a company redraws its segments or changes how it adjusts EPS, it restates the year-ago column, so the year-ago figure in a new release can differ from the one printed a year ago. This page always uses the comparison in the newer release, because that is the like-for-like one.

A walk-through of every line in a release, with what each one tells you, is in how to read an earnings report.